BetterLife To Present BETR-001 Preclinical Data at the Upcoming Federation of European Neuroscience Societies (FENS) Forum

Irwin Naturals Continues To Expand Clinic Footprint

Yale’s Department of Psychiatry Chair to Join Clearmind Medicine

Wellbeing Digital Sciences Announces the Appointment of Natalie Dolphin as VP of Marketing and Investment Relations

Lobe Sciences Ltd. and Clearway Global LLC Enter into a Development Agreement to Manage Lobe Sciences Ltd.'s Global Regulatory and Development Strategy and its Implementation

Ceruvia Lifesciences Submits FDA Investigational New Drug Application for NYPRG-101 Migraine Prevention Program

Red Light Holland Closes Acquisition of 100 Acres of Farmland in Ontario, Canada Expanding its Mushroom Farms Division in North America

Optimi Health Requests Approval To Manufacture MDMA, Other Synthetic Psychedelics

Stephen Bardin to Join atai Life Sciences as CFO Designate

Dr. Alan K. Davis | Director, Center for Psychedelic Drug Research and Education

U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

Irwin Naturals Expands Operations into Northeast with Acquisition of Vermont-Based Clinic

Awakn Life Sciences to Present in Upcoming June 2022 Conferences

MYND Life Sciences Announces Chief Scientific Officer, Dr. Wilf Jefferies, Induction as a National Academy of Inventors Fellow

Psychedelic Weekly Headlines | June 17th

Cybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022